TRHC’s new pharmacotherapy R&D institute to be based in Orlando
By Akshay Kedari  Date: 2019-02-23

TRHC’s new pharmacotherapy R&D institute to be based in Orlando

The newly established research institute will look forward to forging partnerships with significant pharmaceutical and academic entities in the region.

Tabula Rasa HealthCare, Inc., the renowned healthcare technology firm, has made it to the headlines for having declared the launch of its new Scientific Precision Pharmacotherapy Research and Development Institute. Reportedly, the Institute will be based out of Orlando, within Lake Nona Medical City.

According to sources familiar with the knowledge of the matter, TRHC's Research & Development Institute is strongly dedicated to developing proprietary products. These products apparently, will be aimed toward the optimization of medication regimes in order to reduce medical care expenditure, enhance patient outcomes, lower the healthcare service utilization, and manage risk. The Institute will also ensure the validation and recognition of these products from the scientific and regulatory communities.

Reportedly, the research vision of the TRHC Institute expands with the new research initiatives cropping up, inclusive of biomedical engineering systems, translational research, patient-specific information, nanoscale science, data-driven technologies and solutions, and bioinformatics.

According to an official press release by Tabula Rasa HealthCare, Calvin H. Knowlton, the CEO & Chairman of the company, stated that the new research institute intends to focus on enhancing the firm’s decision support tools via extensive research, deploying computer simulations, computational modeling, and pharmacokinetics & pharmacodynamics modeling. The basic objective here is to optimize and manufacture novel products in association with the company’s Medication Risk StratificationTM and Medication Risk MitigationTM technologies, Knowlton claimed.

Dr. Jacques Turgeon, Chief Scientific Officer, TRHC, stated that the institute will aim to forge partnerships with academic and pharmaceutical entities, and also look forward to the opportunity to join hands with globally acclaimed organizations.

Commenting further on the launch, Knowlton affirmed that the company is thrilled to not only be a part of the innovation prevalent in Lake Nona Medical City, but also to have gained the guidance of Dr. Michaud and Dr. Turgeon, stalwarts recognized for their expertise in pharmacokinetics & drug-metabolism and research and pharmacy education respectively.

Dr. Jacques Turgeon, BPharm, PhD, for the record, has been named the CEO of the TRHC Institute, while Dr. Veronique Michaud, BPharm, PhD, will be filling in the place of the institute’s Chief Operating Officer.

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

British officials advise limited role to Huawei in U.K. 5G network
British officials advise limited role to Huawei in U.K. 5G network
By Akshay Kedari

British officials have formally granted Huawei a limited role in the future 5G network of the U.K., dismissing the U.S. calls to completely ban Huawei. The U.S. had earlier accused the company of spying on behalf of the Chinese government.  Off...

Boom and Flight Research to bring XB-1 test flights to Mojave Corridor
Boom and Flight Research to bring XB-1 test flights to Mojave Corridor
By Akshay Kedari

Boom Supersonic, a Colorado based startup that is designing the fastest supersonic airliner in history, has reportedly announced a new strategic partnership deal with Flight Research, Inc., a leading provider of training, services and support activit...

DTM™ spinal cord stimulation shows superior back pain relief in RCT
DTM™ spinal cord stimulation shows superior back pain relief in RCT
By Akshay Kedari

Medtronic plc, a Dublin-based medical technology, services, and solutions company, has reportedly announced three-month results from a large, multicenter RCT (randomized controlled trial) demonstrating statistically meaningful (p=0.0009) and improved...

Mercury Systems, Intel bring in new flight safety-certifiable modules
Mercury Systems, Intel bring in new flight safety-certifiable modules
By Akshay Kedari

Mercury Systems Inc., one of the leading aerospace and defense companies, has recently introduced the first-ever commercially-available compute module, EnsembleSeries™ CIOE-1390 module, embedded with its BuiltSAFE™ technology and Intel&re...

Samsung to pour in $500 million for a new manufacturing unit in India
Samsung to pour in $500 million for a new manufacturing unit in India
By Akshay Kedari

One of the leading smartphone brands, Samsung Electronics is planning to invest $500 million in its Indian business by building a display manufacturing unit in the outskirts of New Delhi. Along with making displays, the new facility would work on man...